Experimental Hematology
Volume 37, Issue 6 , Pages 673-678 , June 2009

Increased plasma EPO and MIP-1α are associated with recruitment of vascular progenitors but not CD34(+) cells in autologous peripheral blood stem cell grafts

  • Laura Labonté

      Affiliations

    • Sprott Centre for Stem Cell Research, Regenerative Medicine Program, Ottawa Health Research Institute, Ottawa, Canada
    • ,
  • Yuhua Li

      Affiliations

    • Sprott Centre for Stem Cell Research, Regenerative Medicine Program, Ottawa Health Research Institute, Ottawa, Canada
    • ,
  • Lin Yang

      Affiliations

    • Stem Cell Processing Laboratory, Canadian Blood Services, Ottawa, Canada
    • ,
  • Akira Gillingham

      Affiliations

    • Stem Cell Processing Laboratory, Canadian Blood Services, Ottawa, Canada
    • ,
  • Michael Halpenny

      Affiliations

    • Stem Cell Processing Laboratory, Canadian Blood Services, Ottawa, Canada
    • ,
  • Antonio Giulivi

      Affiliations

    • Stem Cell Processing Laboratory, Canadian Blood Services, Ottawa, Canada
    • ,
  • Terrence Sills

      Affiliations

    • Ontario Cancer Biomarkers Network, Toronto, Canada
    • ,
  • Kenneth Evans

      Affiliations

    • Ontario Cancer Biomarkers Network, Toronto, Canada
    • ,
  • Brent Zanke

      Affiliations

    • Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, Canada
    • ,
  • David S. Allan

      Affiliations

    • Sprott Centre for Stem Cell Research, Regenerative Medicine Program, Ottawa Health Research Institute, Ottawa, Canada
    • Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, Canada
    • Blood and Marrow Transplant Program, Department of Medicine, University of Ottawa, Ottawa, Canada
    • Corresponding Author InformationOffprint requests to: David Allan, M.Sc., M.D., Hematology and Blood and Marrow Transplantation, The Ottawa Hospital, General Campus, 501 Smyth Road, Box 704, Ottawa, Ontario K1H 8L6 Canada

Received 28 October 2008 ,Revised 5 February 2009 ,Accepted 18 February 2009.

References 

  1. Bensinger WI. Hematopoietic cell transplantation for multiple myeloma. Cancer Control. 1998;5:235–242
  2. Martinez C, Salamero O, Arenillas L, et al. Autologous stem cell transplantation for patients with active Hodgkin's lymphoma: long-term outcome of 61 patients from a single institution. Leukemia Lymphoma. 2007;48:1968–1975
  3. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964–967
  4. Gill M, Dias S, Hattori K, et al. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ Res. 2001;88:167–174
  5. Cho HJ, Kim HS, Lee MM, et al. Mobilized endothelial progenitor cells by granulocyte-macrophage colony-stimulating factor accelerate reendothelialization and reduce vascular inflammation after intravascular radiation. Circulation. 2003;108:2918–2925
  6. Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003;102:1340–1346
  7. Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 2001;103:2885–2890
  8. Allan DS, Dubé P, Roy J, Busque L, Roy DC. Endothelial-like vascular progenitor cells (VPCs) from allogeneic and autologous donors: mobilization features distinct from hematopoietic progenitors. Biol Blood Marrow Transplant. 2007;13:433–439
  9. Iqbal T, Rajagopal T, Halpenny M, et al. Increased graft content of vascular progenitor cells is associated with reduced toxicity following autologous hematopoietic transplantation. Exp Hematol. 2008;36:506–512
  10. Hill JM, Zalos G, Halcox JPJ, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348:593–600
  11. Bearman SI, Appelbaum FR, Buckner D, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6:1562–1568
  12. Keeney M, Chin-Yee I, Weir K, et al. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering. Cytometry. 1998;34:61–70
  13. Kasbia G, Al-Gahtani F, Tay J, et al. Reduced hemoglobin on day of peripheral blood progenitor cell collection is associated with low graft content of vascular progenitors and increased toxicity after autologous hematopoietic stem cell transplantation. Transfusion. 2008;48:2421–2428
  14. Urao N, Okigaki M, Yamada H, et al. erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res. 2006;98:1405–1413
  15. Bahlmann FH, de Groot K, Spandau JM, et al. Erythropoietin regulates endothelial progenitor cells. Blood. 2004;103:921–926
  16. Labonté L, Iqbal T, McDiarmid S, et al. Erythropoietin during PBPC collection: can we reduce toxicity of autologous transplants in multiple myeloma. Biol Blood Marrow Transplant. 2008;14:132–133
  17. Burger D, Lei M, Geoghegan-Morphet N, Lu X, Xenocostas A, Feng Q. Erythropoietin protects cardiomycocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc Res. 2006;72:51–59
  18. Cook DN. The role of MIP-1α in inflammation and hematopoiesis. J Leukocyte Biol. 1996;59:61–66
  19. Su S, Mukaida N, Wang J, et al. Inhibition of immature erythroid progenitor cell proliferation by macrophage inflammatory protein-1 alpha by interacting mainly with a C-C chemokine receptor, CCR1. Blood. 1997;90:605–611
  20. Holler E, Kolb HJ, Moller A. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75:1011–1016
  21. Bianco JA, Appelbaum FR, Nemunaitis J, et al. Phase I–II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood. 1991;78:1205–1211
  22. Pober JS. Effects of tumour necrosis factor and related cytokines on vascular endothelial cells. Ciba Found Symp. 1987;131:170–184
  23. Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology. 2005;115:1–20

PII: S0301-472X(09)00058-7

doi: 10.1016/j.exphem.2009.02.010

Experimental Hematology
Volume 37, Issue 6 , Pages 673-678 , June 2009

Article Tools

* Image Usage & Resolution